Single User
£4350
PDF
82 pages

Graves’ Disease Forecast in 23 Major Markets 2017-2027


Graves’ disease is an autoimmune disease of the thyroid gland, in which the thyroid attacked by the body’s own defence mechanisms becomes enlarged and produces increased amount of hormones, causing hyperthyroidism. The condition induces signs and symptoms that seriously affect the patient’s quality of life, everyday activities and ability to work.

This report provides the current prevalent population for Graves’ disease across 23 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, The Netherlands, Norway, Sweden, Austria, Denmark, Iceland, Switzerland, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Graves’ disease have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

The quantified symptoms and co-morbidities for Graves’ disease include:

  • Graves' Ophthalmopathy
  • Acropachy
  • Thyroid dermopathy

Moreover, forecasts of some clinical and family history parameters are provided at a country level.

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy
  • Able to quantify patient populations in global Graves’ disease’s market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of Graves’ disease and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on Graves’ disease’s prevalent population.
  • Identify sub-populations within Graves’ disease which require treatment.
  • Gain an understanding of the specific markets that have the largest number of Crohn’s disease patients.

CONTENTS

  • LIST OF TABLES AND FIGURES
  • INTRODUCTION
  • CAUSE OF THE DISEASE
  • RISK FACTORS & PREVENTION
  • DIAGNOSIS OF THE DISEASE
  • VARIATION BY GEOGRAPHY/ETHNICITY
  • DISEASE PROGNOSIS & CLINICAL COURSE
  • KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE
  • METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS
  • TOP-LINE PREVALENCE FOR GRAVES’ DISEASE
  • FEATURES OF GRAVES’ DISEASE PATIENTS
  • COMORBID CONDITIONS OF GRAVES’ DISEASE PATIENTS
  • ABBREVIATIONS USED IN THE REPORT
  • OTHER BLACK SWAN ANALYSIS PUBLICATIONS
  • BLACK SWAN ANALYSIS ONLINE PATIENT-BASED DATABASES
  • PATIENT-BASED OFFERING
  • ONLINE PRICING DATA & PLATFORMS
  • REFERENCES
  • APPENDIX

LIST OF TABLES AND FIGURES

  • Table 1. Prevalence of Graves’ disease, total (000s)
  • Table 2. Prevalence of Graves’ disease, males (000s)
  • Table 3. Prevalence of Graves’ disease, females (000s)
  • Table 4. Goitre status at diagnosis (000s)
  • Table 5. First Line Treatment Option (000s)
  • Table 6. Graves’ Disease Patients with Graves' Ophthalmopathy, total (000s)
  • Table 7. Graves’ Disease Patients with Acropachy, total (000s)
  • Table 8. Graves’ Disease Patients with a Family History of Thyroid Dysfunction, total (000s)
  • Table 9. Graves’ Disease Patients with Thyroid Dermopathy, total (000s)
  • Table 10. Abbreviations and Acronyms used in the report
  • Table 11. USA Prevalence of Graves’ Disease by 5-yr age cohort, males (000s)
  • Table 12. USA Prevalence of Graves’ Disease by 5-yr age cohort, females (000s)
  • Table 13. Canada Prevalence of Graves’ Disease by 5-yr age cohort, males (000s)
  • Table 14. Canada Prevalence of Graves’ Disease by 5-yr age cohort, females (000s)
  • Table 15. France Prevalence of Graves’ Disease by 5-yr age cohort, males (000s)
  • Table 16. France Prevalence of Graves’ Disease by 5-yr age cohort, females (000s)
  • Table 17. Germany Prevalence of Graves’ Disease by 5-yr age cohort, males (000s)
  • Table 18. Germany Prevalence of Graves’ Disease by 5-yr age cohort, females (000s)
  • Table 19. Italy Prevalence of Graves’ Disease by 5-yr age cohort, males (000s)
  • Table 20. Italy Prevalence of Graves’ Disease by 5-yr age cohort, females (000s)
  • Table 21. Spain Prevalence of Graves’ Disease by 5-yr age cohort, males (000s)
  • Table 22. Spain Prevalence of Graves’ Disease by 5-yr age cohort, females (000s)
  • Table 23. UK Prevalence of Graves’ Disease by 5-yr age cohort, males (000s)
  • Table 24. UK Prevalence of Graves’ Disease by 5-yr age cohort, females (000s)
  • Table 25. Poland Prevalence of Graves’ Disease by 5-yr age cohort, males (000s)
  • Table 26. Poland Prevalence of Graves’ Disease by 5-yr age cohort, females (000s)
  • Table 27. The Netherlands Prevalence of Graves’ Disease by 5-yr age cohort, males (000s)
  • Table 28. The Netherlands Prevalence of Graves’ Disease by 5-yr age cohort, females (000s)
  • Table 29. Norway Prevalence of Graves’ Disease by 5-yr age cohort, males (000s)
  • Table 30. Norway Prevalence of Graves’ Disease by 5-yr age cohort, females (000s)
  • Table 31. Sweden Prevalence of Graves’ Disease by 5-yr age cohort, males (000s)
  • Table 32. Sweden Prevalence of Graves’ Disease by 5-yr age cohort, females (000s)
  • Table 33. Austria Prevalence of Graves’ Disease by 5-yr age cohort, males (000s)
  • Table 34. Austria Prevalence of Graves’ Disease by 5-yr age cohort, females (000s)
  • Table 35. Denmark Prevalence of Graves’ Disease by 5-yr age cohort, males (000s)
  • Table 36. Denmark Prevalence of Graves’ Disease by 5-yr age cohort, females (000s)
  • Table 37. Iceland Prevalence of Graves’ Disease by 5-yr age cohort, males (000s)
  • Table 38. Iceland Prevalence of Graves’ Disease by 5-yr age cohort, females (000s)
  • Table 39. Switzerland Prevalence of Graves’ Disease by 5-yr age cohort, males (000s)
  • Table 40. Switzerland Prevalence of Graves’ Disease by 5-yr age cohort, females (000s)
  • Table 41. Turkey Prevalence of Graves’ Disease by 5-yr age cohort, males (000s)
  • Table 42. Turkey Prevalence of Graves’ Disease by 5-yr age cohort, females (000s)
  • Table 43. Japan Prevalence of Graves’ Disease by 5-yr age cohort, males (000s)
  • Table 44. Japan Prevalence of Graves’ Disease by 5-yr age cohort, females (000s)
  • Table 45.China Prevalence of Graves’ Disease by 5-yr age cohort, males (000s)
  • Table 46. China Prevalence of Graves’ Disease by 5-yr age cohort, females (000s)
  • Table 47. South Korea Prevalence of Graves’ Disease by 5-yr age cohort, males (000s)
  • Table 48. South Korea Prevalence of Graves’ Disease by 5-yr age cohort, females (000s)
  • Table 49. India Prevalence of Graves’ Disease by 5-yr age cohort, males (000s)
  • Table 50. India Prevalence of Graves’ Disease by 5-yr age cohort, females (000s)
  • Table 51. Australia Prevalence of Graves’ Disease by 5-yr age cohort, males (000s)
  • Table 52. Australia Prevalence of Graves’ Disease by 5-yr age cohort, females (000s)
  • Table 53. Brazil Prevalence of Graves’ Disease by 5-yr age cohort, males (000s)
  • Table 54. Brazil Prevalence of Graves’ Disease by 5-yr age cohort, females (000s)
  • Table 55. Mexico Prevalence of Graves’ Disease by 5-yr age cohort, males (000s)
  • Table 56. Mexico Prevalence of Graves’ Disease by 5-yr age cohort, females (000s)
Austria, Brazil, Canada, China, Denmark, France, Germany, Iceland, India, Italy, Japan, Mexico, Netherlands, Norway, Poland, Republic of Korea, Spain, Sweden, Switzerland, Turkey, United Kingdom, United States of America